tirzepatide hot flashes Menopause, & HRT: The Metabolic “Multiplier" In the OASIS-3 phase 3

GLP-1 drugs are primarily recommended for: Adults with type 2 diabetes who arent seeing results from oral medications and need better blood sugar control People with obesity or with a BMI over 30 (with or without diabetes) seeking medical weight management Doctors may also consider GLP-1 RAs for patients with cardiovascular risk factors, as some of these drugs have shown heart-protective benefits

The implementation of a retatrutide dosage calculator can also streamline the workflow in clinical settings

Tirzepatide frequently causes nausea (12-22% of patients), diarrhea (12-16%), vomiting (6-10%), constipation (6-7%), and abdominal discomfort, particularly during dose escalation

Blood pressure improvements appear early in treatment